Candel Therapeutics, Inc. (CADL)

Over the past six months, Candel Therapeutics' stock price has been influenced by several events. In February 2026, the company announced inducement grants, with the share price decreasing by -10.79% from the prior week. In January 2026, analysts noted the company was nearing breakeven, with anticipated profits in 2028. In December 2025, Candel reported positive topline data from its Phase 3 trial of CAN-2409 in prostate cancer, expecting to support a BLA submission, and hosted a virtual R&D event. In November 2025, the company reported its Third Quarter 2025 financial results, and Freedom Capital Markets raised its price target to $14.00. In October 2025, Candel announced positive interim Phase 1b data for CAN-3110 in recurrent glioblastoma and secured a $130 million term loan facility. In September 2025, BofA Securities downgraded Candel Therapeutics from Buy to Neutral with a $7 price target. In August 2025, Candel reported its Second Quarter 2025 financial results. The stock's 52-week high was $13.68, and its 52-week low was $4.25.

As a clinical-stage biopharmaceutical company, Candel Therapeutics does not have commercialized products or services, so there is no demand seasonality. The company's performance is driven by clinical trial progress, regulatory milestones, and funding activities.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for solid tumors. The company engineers viruses to induce immunogenic cell death in cancer cells, releasing tumor neo-antigens and creating a pro-inflammatory microenvironment to generate a systemic immune response. Candel has two primary oncolytic viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its lead product candidates include CAN-2409, in Phase III trials for prostate cancer and Phase II trials for pancreatic and non-small cell lung cancer, and CAN-3110, in a Phase I trial for recurrent high-grade glioma. The company also utilizes its enLIGHTEN Discovery Platform to create new viral immunotherapies.

Candel Therapeutics, Inc. is headquartered in Needham, Massachusetts, and conducts clinical trials across multiple sites in North America and Europe.

Candel Therapeutics builds its reputation through clinical trial results and pipeline advancements. The company has a consensus rating of "Moderate Buy" from analysts, with an optimistic outlook from the investment community. Positive clinical trial data for CAN-2409 and CAN-3110, along with FDA Fast Track designation, have contributed positively to its reputation. A notable short interest exists, but no specific events negatively impacting its brand reputation were found.

Candel Therapeutics stock ownership is distributed among institutional, retail, and individual investors. Approximately 35.48% is owned by Institutional Investors, 19.77% by Insiders, and 44.75% by Public Companies and Individual Investors. Major institutional owners include Fmr Llc, Acorn Capital Advisors, Llc, BlackRock, Inc., and Vanguard Group Inc.